Here, CHIP mutations are found to disrupt degradation of phosphodiesterase PDE9A, with the CHIP-PDE9A interaction representing a potential therapeutic target for restoring cerebellar neuronal function and preventing degeneration in CHIP-related ataxia. The gene discussed is PDE9A; the disease is Ataxia.